Literature DB >> 9834364

Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer.

S B Hosch1, A J Meyer, C Schneider, N Stoecklein, K L Prenzel, K Pantel, C E Broelsch, J R Izbicki.   

Abstract

Most solid malignancies show some degree of lymphoid infiltration suggesting a specific immunologic host vs. tumor reaction. Tumor-infiltrating lymphocytes (i.e., CD3 + T-lymphocyte subsets), the human leukocyte antigen (HLA) class I molecules, and the intercellular adhesion molecule-1 (ICAM-1) are key factors involved in T-cell-mediated immune surveillance. The present study was designed to assess the expression pattern of intratumoral lymphocyte infiltrates and their relationship to HLA class I and ICAM-1 expression with regard to primary esophageal carcinoma and to evaluate their prognostic influence. Representative samples of primary tumors were obtained from 55 patients who had undergone radical en bloc esophagectomy. Frozen sections of these tumors were stained with monoclonal antibodies directed against CD3 for the assessment of tumor-infiltrating lymphocytes, HLA class I, and ICAM-1. The mean postoperative observation period was 19.5 months (range 5 to 45 months). Lymphocyte infiltration was absent in four tumors (8%), whereas 31 tumors (64%) showed moderate and 13 (27%) showed strong infiltration. HLA class I expression was deficient in 24 tumors (45%). Coexpression of HLA class I and ICAM-1 was significantly associated with lymphocyte infiltration of the tumor. Kaplan-Meier analyses revealed a significant beneficial influence on relapse-free survival for patients with lymphocyte infiltration of primary tumors compared to those with no lymphocyte infiltration of tumors (median 4 months vs. 18 months; P <0.002) and for HLA class I+ tumors compared to HLA class I- tumors (median survival >18 months vs. 7 months; P = 0.0081). The present data support the hypothesis that T-cell-mediated immunity may influence the fate of patients with esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9834364     DOI: 10.1016/s1091-255x(97)80051-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  [Squamous cell cancer of the esophagus. Treatment concept at the surgical clinic of the Munich Technical University].

Authors:  J R Siewert; H Bartels; E Bollschweiler; H J Dittler; U Fink; A H Hölscher; J D Roder
Journal:  Chirurg       Date:  1992-09       Impact factor: 0.955

2.  Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours.

Authors:  B M Vose; M Moore
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

3.  Clonal analysis of human tumor infiltrating lymphocytes reactive with autologous tumor cells: different target cell specificities of NK-like and cytotoxic T-cell clones.

Authors:  H Rabinowich; Z Steiner; A Klajman
Journal:  Cell Immunol       Date:  1987-02       Impact factor: 4.868

4.  Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II. Functional investigations of the infiltrating inflammatory cells.

Authors:  T H Tötterman; P Häyry; E Saksela; T Timonen; B Eklund
Journal:  Eur J Immunol       Date:  1978-12       Impact factor: 5.532

5.  Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial.

Authors:  M Goldminc; G Maddern; E Le Prise; B Meunier; J P Campion; B Launois
Journal:  Br J Surg       Date:  1993-03       Impact factor: 6.939

6.  Different cytoplasmic structure of the CD3 zeta family dimer modulates the activation signal and function of T cells.

Authors:  T Aoe; S Goto; H Ohno; T Saito
Journal:  Int Immunol       Date:  1994-11       Impact factor: 4.823

7.  Modification of natural killer activity of lymphocytes infiltrating human lung cancers.

Authors:  T M Anderson; Y Ibayashi; E C Holmes; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients.

Authors:  S M Alam; J S Clark; V Leech; P Whitford; W D George; A M Campbell
Journal:  Immunol Lett       Date:  1992-02-15       Impact factor: 3.685

9.  The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.

Authors:  G A Van Seventer; Y Shimizu; K J Horgan; S Shaw
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity.

Authors:  O Eremin; R R Coombs; J Ashby
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

View more
  6 in total

Review 1.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

2.  Investigation of intercellular adhesion molecules (ICAMs) gene expressions in patients with Barrett's esophagus.

Authors:  Belgin Alasehirli; Elif Oğuz; Ebru Oksuzler; Irfan Koruk; Serdar Oztuzcu; Esma Ozkara; Metin Karakok; Ayse Binnur Erbagcı; Abdullah Tuncay Demiryurek
Journal:  Tumour Biol       Date:  2014-01-29

3.  Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Authors:  Melina Schellhorn; Maria Haustein; Marcus Frank; Michael Linnebacher; Burkhard Hinz
Journal:  Oncotarget       Date:  2015-11-17

Review 4.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

5.  Defective HLA class I antigen processing machinery in cancer.

Authors:  Lei Cai; Theodoros Michelakos; Teppei Yamada; Song Fan; Xinhui Wang; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Cancer Immunol Immunother       Date:  2018-02-27       Impact factor: 6.968

6.  Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.

Authors:  Y Mizukami; K Kono; T Maruyama; M Watanabe; Y Kawaguchi; K Kamimura; H Fujii
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.